Nonalcoholic fatty liver disease and serum uric acid

• Main Authors: XU Beibei, WANG Bingyuan
• Format: Article
• Language: zho
• Published: Editorial Department of Journal of Clinical Hepatology 2016-03-01
• Series: Linchuang Gandanbing Zazhi
• Online Access: http://www.lcgdbzz.org/qk_content.asp?id=7235

Nonalcoholic fatty liver disease (NAFLD) is considered the manifestation of metabolic syndrome (MS) in the liver. Besides glucose and lipid metabolic disorders, the level of serum uric acid (SUA) is also associated with the progression of NAFLD. This article reviews the research achievements in the association between SUA and NAFLD and points out that SUA can independently predict the risks of MS, type 2 diabetes, and cardiovascular disease in both healthy people and patients. Its mechanism may be that SUA increases the expression of reactive oxygen species (ROS)/thioredoxin-interacting protein (TXNIP) through inducing ROS, and then it activates the NLR pyrin domain containing 3 inflammasome and induces the secretion of interleukin. Both basic and clinical research show that the drugs reducing SUA can inhibit the TXNIP pathway, reduce the blood glucose level, and alleviate liver ROS, inflammation, steatosis, and fibrosis. This article suggests that SUA may be a promising therapeutic method for NAFLD and needs further basic and clinical research.